

3/2023

**EFGARTIGIMOD ALFA-FCAB (VYVGART) Infusion** 

NAME: **INSURANCE:** PROVIDER NAME: **CLINIC NAME and Phone number:** 

**Patient identification** 

<b>W</b> eight:	kg Height:	cm Allergies:	Diagnosis Code:						
Treatme	ent Start Date:								
**If trea	atment not started within 90	days, new orders witl	n updated date/signature will be required. Otherwise,						
orders a	are valid for 1 year from signa	ture date.**							
GUIDEL	INES FOR ORDERING:								
1)		<u>th</u> must be on EACH p	age of this order form. This form will be returned if any						
	left blank.								
2)	) Send FACE SHEET and complete copy of INSURANCE information. Send H&P or most recent chart note								
	must be within the past 12 m								
3)	Send a copy of related lab re		· · · · · · · · · · · · · · · · · · ·						
4)			, this is the responsibility of ordering provider.						
Recomn	mended Pre-screening labs: Se	end any applicable res	ults from list below.						
•	Confirm patient is anti-acety	choline receptor (ACh	R) antibody positive.						
MEDICA									
$\checkmark$		•	chloride 0.9% 125 mL IVPB, infuse over 1 hour. Use 0.2						
		nistration. Keep in refr	igerator. Do not shake. Monitor patient for 1 hour afte						
	infusion.								
DOSE: (	must select one)								
	<u> </u>		the top of this form. Maximum dose is 1200 mg, dose						
	will be rounded down to this								
		m dose & recommend	ed for patient's weighing 120 kg or more.						
	NCY: (must select one)								
	Give once a week for 4 week								
			ery 84 days (about 12 weeks).						
	Give once a week for 4 week	s. Repeat this cycle ev	ery						
_	DED MEDICATIONS:								
		olus 250 ml, Flush befo	ore and after IV medication(s) and as needed with NS.						
	d included Nursing Orders:								
			on in patients with an active infection until resolved.						
	Observe patient for 60 minut	•							
$\checkmark$	Vital signs: Monitor and reco	rd vital signs, tolerand	e, and presence of infusion-related reactions prior to						

- infusion and at the end of infusion. ✓ Insert peripheral IV if no iv access.
- ✓ May use/access CVC line and give 500 units (5ml) heparin injection for central line care.
- ✓ If hypersensitivity or infusion reactions develop, temporarily hold the infusion, and notify provider immediately. Include hypersensitivity reaction order set. (See attached form).

## HYPERSENSITIVITY INFUSION REACTION ORDERS

## **STOP** infusion if:

MILD REACTION: Localized pruritus, rhinitis, localized rash, fever greater than 38 degrees C.

- 1. Stop infusion and maintain IV access with NS line.
- 2. Notify MD of symptoms and infusion reaction orders initiated.

MODERATE REACTION: Generalized pruritus, generalized flushing, rash, back pain, mild dyspnea, chills, hypotension with SBP less than 90 mmHg or greater than 20% decrease in SBP.



**EFGARTIGIMOD ALFA-FCAB (VYVGART) Infusion** 

NAME:
BIRTHDATE:
INSURANCE:
PROVIDER NAME:
CLINIC NAME and Phone number:

**Patient identification** 

- 1. Stop infusion, but do not discard infusion bag/bottle unless instructed by MD that therapy is to be discontinued.
  - 2. Maintain IV access with NS line.
  - 3. Place patients in a supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
  - 4. Maintain airway.

**SEVERE REACTION:** Respiratory distress (bronchospasm, stridor, wheezing, persistent cough, respiratory depression, cardiac arrhythmia, chest pain, generalized urticaria (hives), syncope, gastrointestinal symptoms (abdominal pain, N/V, diarrhea), hypotension SBP less than 80 mmHg, face/throat/tongue swelling, shock, loss of consciousness.

- 1. Stop infusion, but do not discard bag/bottle unless instructed by MD that therapy is to be discontinued.
- 2. Stay with patient and have another nurse notify MD of symptoms and infusion reaction orders initiated.
- 3. Place patients in supine position with lower extremities elevated unless respiratory distress or nausea/vomiting.
- 4. Maintain airway.
- 5. Maintain IV access with NS line.
- 6. Inpatients: Activate code blue for loss of blood pressure, pulse, or consciousness.

## **MEDICATIONS:**

- Acetaminophen (TYLENOL) tablet 650 mg, Oral, EVERY 4 HOURS PRN, Pain, Other, Mild reaction. Starting when released.
- DiphenhydrAMINE (Benadryl) injection, 25 mg, Intravenous, EVERY 15 MIN PRN, Moderate or severe reaction, may repeat x1. Starting when released, For 2 doses.
- Methylprednisolone sodium succinate (solu-MEDROL) 62.5mg/ml injection, 125 mg, Intravenous, ONCE PRN, Severe reaction. Starting when released, For 1 dose. Mix with 2 mL provided diluent to make 62.5 mg/mL.
- Famotidine (PEPCID) injection 20 mg, Intravenous, ONCE PRN, Moderate reaction, or anaphylaxis, starting when released. Dilute 2 mL of famotidine with 8 mL of normal saline to a final concentration of 2 mg/mL. Administer ordered dose over a period of at least 2 minutes.
- Albuterol 90 mcg/puff inhaler 2 puff, Inhalation, ONCE PRN, Severe reaction p. Starting when released, For 1 dose. Shake well. Use with spacer.
- Start oxygen. For MODERATE Reaction: Start 2 liters O2 per nasal cannula as needed for SpO2 less than 93%. For SEVERE Reaction: Start continuous pulse oximetry. Administer 6 to 8 liters per minute (LPM) via face mask, or up to 100% oxygen to maintain oxygen saturation greater than 90%.
- EPINEPHrine 1 mg/mL injection 0.3 mg. Intramuscular, EVERY 5 MIN PRN, Anaphylaxis. Starting when released, For 3 doses. Administer in the anterior lateral thigh using 1 - 1.5-inch needle for airway obstruction symptoms and/or hypotension.
- Sodium chloride 0.9% (NS) infusion 500ml. At 500 mL/hr., Intravenous, PRN, Moderate reaction, or anaphylaxis. Starting when released. Run wide open to gravity.



3/2023

**EFGARTIGIMOD ALFA-FCAB (VYVGART) Infusion** 

□ NEWBERG

NAME: **INSURANCE: PROVIDER NAME: CLINIC NAME and Phone number:** 

**Patient identification** 

		w, I represent the follow				
	-	e for the care of the patie				
l hold i	an active,	unrestricted license to p	ractice medicine ir	Oregon	1.	
My ph	ysician lic	cense Number is #	a	nd I am a	acting within my scope of practice and	
					roducts described above for the patier	
identif	ied on thi	s form.				
Prov	/ider's pri	inted name:				
		nature:				
	e:					
	-	e the following intake qu	iestions.			
	ty status					
	Indepe					
	Walker					
	Wheelchair					
	· -	ependent				
	ric needs					
	Yes, br	iefly describe		-		
	_					
		concerns				
	Yes, br	iefly describe		_		
	No					
Interp	reter Serv	vice required				
	Yes, lar	nguage				
	No					
Outpa	tient Infu	sion Services Intake Tear	m:			
		e appropriate box for the		ed infusi	ion center location:	
	П	PORTLAND	Phone- <b>503-21</b> 5	5-6046 F	Fax- <b>503-487-3582</b>	
	<del></del>	WILLAMETTE FALLS				
		MEDFORD			Fax- <b>541-732-3939</b>	
		HOOD RIVER				
			Phone- <b>503-71</b> 7			

Phone-**503-537-6040** Fax-**503-205-8720**